Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 2/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 5/20 | 0.35 |
| ▸ | CDK8 | P49336 | 5/20 | 0.35 |
| ▸ | CDK19 | Q9BWU1 | 5/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 5/20 | 0.32 |
| ▸ | FNTB | P49356 | 5/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551995 | 0.85 | GRIA4 (0.57) | GRIA4GRIA2ALDH1A1FNTAFNTB | |
| SCHEMBL3403380 | 0.83 | GRIA4 (0.45) | GRIA4GRIA2ALDH1A1GAANPSR1 | |
| SCHEMBL6644214 | 0.82 | GRIA4 (0.47) | GRIA4GRIA2ALDH1A1MAPK1HTT | |
| SCHEMBL622911 | 0.79 | KDM4E (0.49) | ALDH1A1NPSR1L3MBTL1FNTAFNTB | |
| SCHEMBL3133960 | 0.78 | GAA (0.47) | ALDH1A1MAPK1GAANPSR1L3MBTL1 | |
| SCHEMBL3128132 | 0.74 | GRIA2 (0.42) | GRIA4GRIA2ALDH1A1MAPK1GAA | |
| SCHEMBL1552287 | 0.73 | GRIA2 (0.43) | GRIA4GRIA2ALDH1A1MAPK1GAA | |
| SCHEMBL3818516 | 0.72 | GRIA4 (0.57) | GRIA4GRIA2ALDH1A1MAPK1HTT | |
| SCHEMBL9864594 | 0.72 | GRIA4 (0.47) | GRIA4GRIA2ALDH1A1MAPK1HTT | |
| SCHEMBL6645082 | 0.72 | GRIA4 (0.39) | GRIA4GRIA2ALDH1A1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250160-B1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARM INC (US) | 2015-11-11 | — | — | EP | disclosed |
| EP-2250160-B1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARM INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029411-B2 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2313399-B1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2313399-B1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325925-A1 | Thiophenes and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009154741-A1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154741-A1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094224-A1 | THIOPHENES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075951-A1 | Heteroaryls and uses thereof | PIK3R3, AKT1S1, PIK3R1 | GRIA4 4190/4885GRIA2 2729/4885ALDH1A1 1931/4885 |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | PIK3R3, AKT1S1, PIK3R1 | GRIA4 4190/4885GRIA2 2729/4885ALDH1A1 1931/4885 |
| US-20090325925-A1 | Thiophenes and uses thereof | PIK3CA, JAK2, MTOR | GRIA4 2350/4885GRIA2 2570/4885ALDH1A1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.